Tocilizumab is a recombinant humanized monoclonal antibody against interleukin(IL)- 6 receptor (IL - 6R). It can prevent IL - 6 from binding to membrane - bound or soluble IL - 6R,thus blocking IL - 6 mediated signal transduction,and clinically alleviating inflammation and joint destruction in rheumatoid arthritis(RA). Both in the American and European Union,intravenous Tocilizumab has been approved for the treatment of both systemic juve-nile idiopathic arthritis(sJIA)and polyarticular JIA(pJIA)in patients aged ﹥ 2 years old. The approval was based on the favorable results from 2 randomized,double - blind,placebo - controlled,multinational,phase Ⅲ trials conducted in patients aged 2 - 17 years old with active sJIA or pJIA. Tocilizumab was generally well tolerated in patients with sJIA and pJIA. The most frequently reported adverse events in Tocilizumab recipients were infections,neutropenia,impaired liver function,etc.

Objective:To investigate the synthetic therapy effect and prognosticfactorsin 107 patientswith breastcancer and explore the relationship between some clinical-pathological factors and patients' prognosis.Methods:Between Jan,2000 and Dec,2003,the clinical-pathological materials of 107 breast cancer cases who have received synthetic therapy,including radiotherapy,surgery,chemotherapy and endocrine therapy,were analyzed.The correlation of age,menopausal status,tumor size,axillary lymph nodal status,TNM stage,hormone receptor status and endocrinetherapy with prognosis of breast cancer was evaluated.Results:The overall survival and disease-free survival of the whole patients were 90.3 and 74.8 months,respectively.Analysis revealed that overall survival and disease-free survival of this group were significantly associated with tumor size,axillary lymph nodal status and TNMstage(P0.05).Conclusion:Our data demonstrate that tumor size,axillary lymph nodal status and TNM stage are significant independent indicators of prognosis in breast cancer respectively,and age,menopausal status,hormone receptor status and endocrine therapy are not significant factors of prognosis.

Kimura's disease is a rare, benign, slow-growing chronic inflammatory swelling with a predilection for the head and neck region and is almost always with peripheral blood eosinophilia and elevated serum IgE levels. It is endemic in Asian males and rare in Western people. Surgical excision of the lesion is the first line therapy. Drug and radiation therapy have to be considered for the refractory lesions.
Angiolymphoid Hyperplasia with Eosinophilia ; diagnosis ; Asian Continental Ancestry Group ; Eosinophilia ; pathology ; Humans ; Immunoglobulin E ; blood ; Inflammation ; pathology ; Male ; Neck ; pathology

Objective To study clinical effect of oral montelukast therapy in the treatment of 35 children with cough variant asthma.Methods 35 children with cough variant asthma were divided into the control group (17 cases)and observation group(18 patients).The control group was given oral procaterol hydrochloride,patients in the observation group were given oral montelukast sodium on the basis of taking procaterol hydrochloride.Results The total effective rate of the observation group (94.44%) was significantly higher than the control group (64.71%),the difference between the two groups was statistically significant (χ2 =4.832,P <0.05).In the two groups before and after treatment the maximum peak expiratory flow rate change had no statistically significant difference (P >0.05).After treatment,the FEV of the observation group (12.81 ±0.34)L was higher than that of the control group(2.32 ±0.45 )L,the difference between the two groups was statistically significant(χ2 =3.648, P <0.05).The FVC of the observation group (3.44 ±0.21)L was higher than the control group (2.98 ±0.15)L, the difference between the two groups was statistically significant (χ2 =7.417,P <0.05).The FEV1 /FVC of the observation group (68.31 ±6.44)was higher than that of the control group (58.46 ±6.49),the difference between the two groups was statistically significant (χ2 =4.505,P <0.05).The cough relief time of the observation group (4.45 ±1.32)d was lower than the control group (6.33 ±2.46)d,the difference between the two groups was statistically significant (χ2 =3.151,P <0.05).The cough symptoms disappear time of the observation group (7.63 ±1.96)d was shorter than the control group (10.61 ±1.84)d,the difference between the two groups was statistically significant (χ2 =4.639,P <0.05).In the two groups before and after treatment the liver and kidney function and blood,urine routine had no significant changes.No adverse reaction occurred during the treatment.Conclusion Steiner conven-tional therapy combined with montelukast in the treatment of children with cough variant asthma can rapidly relieve symptoms of cough,significantly improve lung function,reduce the recurrence rate,no adverse reactions,and signifi-cantly improve clinical efficacy,it is worthy of clinical application.

Objective: To compare the safety and efifcacy of rivaroxaban and warfarin for treating the patients with left ventricular thrombus. Methods: A total of 31 patients with left ventricular thrombus were studied, the patients were randomly divided into 2 groups:Warfarin group, n=16, the patients initially received oral warfarin and low molecular weight heparin at (2.5-3) mg/day, when the INR value reached 2.0-3.0, heparin was stopped and warfarin was continued, the INR value was monitored every 3 days for 3 times, when INR value was stably kept at 2.0-3.0, it was then monitored for every 2 weeks. Rivaroxaban group,n=15, the patients received oral rivaroxaban at 10 mg twice a day. All patients were followed-up for 3 months, the thrombus remission time, new onset of thrombosis, embolism and bleeding events during treatment period were compared between 2 groups. Results: The patients’ age, gender, complication, size of thrombus and medication were similar between 2 groups. Compared with Warfarin group, Rivaroxaban group had the shorter thrombus remission time, (60.00±5.50)d vs (71.00±8.50) d,P<0.01, while the new onset of thrombosis and embolism events as cerebral embolism and systemic embolism were similar between 2 groups, Warfarin group had slightly higher bleeding events, allP>0.05. Conclusion: Rivaroxaban had better effect than warfarin for treating the patients with left ventricular thrombus without increasing the risk of bleeding.

Gut microbiota is essential to human health,playing a major role in the bidirectional communication between the gastrointestinal tract and the central nervous system through the immunological,hormonal,neural and metabolic pathways.The colonization of the gut microbiota is influenced by multiple and diverse factors,such as the perinatal factors,dietary habits,diseases and antibiotics.The infant is the critical period for modifying the gut microbiota,disruptions during this period of microbiota-host interaction have the potential to affect the development and function of the brain.To regulate the homeostasis of the gut microbiota has its profound influences on improving the symptoms of gastrointestinal and behavior disorders.

BACKGROUND:Heart transplantation is an effective method for treatment of end-stage heart failure, but immune rejection that seriously impact therapeutic effacicy is easy to occur after transplantation. OBJECTIVE:To investigate the regulatory effect of bone marrow mesenchymal stem cel s on the immune function of rats undergoiong heart transplantation. METHODS:Twenty Lewis rats were enrol ed as donors, and 20 Wistar rats as recipients. Heart transplantation models were established in the Wistar rats. These 20 model rats were randomized into cel transplantation and control group with 10 rats in each group. Forty-eight hours after heart transplantation, rats in the cel transplantation group were given bone marrow mesenchymal stem cel suspension (1 mL, 2×108 cel s/L) via the tail vein, while rats in the control group were given normal saline in the same dose. Then, the expression levels of serum interleukin-2, interleukin-10 and percentage of CD4+, CD8+, CD4+/CD8+, CD4+CD25high, CD4+CD25high Foxp3+T cel s in the venous blood were detected in the two groups at 7 days after cel transplantation. Additional y, rat myocardial tissues were taken and observed pathological y. RESULTS AND CONCLUSION:The survival time of the cel transplantation group was significantly longer than that of the control group (P<0.05). The expression level of interleukin-2 showed no significant difference between the two groups (P>0.05), but the level of interleukin-10 in the cel transplantation group was significantly higher than that in the control group (P<0.05). Compared with the control group, the percentage of CD4+/CD8+, CD4+CD25high, CD4+CD25high Foxp3+and CD4+T cel s was significantly higher, and the percentage of CD8+T cel s was significantly lower in the cel transplantation group (P<0.05). Histopathological findings showed that there were a smal amount of infiltrated lymphocytes in the cel transplantation group with the presence of slight bleeding and edema, and these inflammatory reactions were milder than those in the control group. These findings indicate that bone marrow mesenchymal stem cel transplantation can effectively reduce the rejection in rats undergoing heart transplantation.

Objective To compare the different effect of two gastric tube insertion methods in pa-dents undergoing computed tomographic virtual endoscopy. Methods 56 patients undergoing computed tomographic virtual endoscopy were randomly divided into group A and B according to gastric tube insertion methods, group A inserted gastric tube to descending duodenum by gastroscope, group B inserted by Jag precursor via nose. One- time success rate and the incidence rate of side effect were compared between the two groups. X2 test was adopted. Results One- time success rate of group A and B was 33.3%, 82.9% respectively, with obvious statistic difference. The incidence rate of side effect of group A was higher than that of group B. Conclusions Inserting gastric tube to descending duodenum by Jag precursor via nose is convenient, time- saving, causing less pain and resulting in higher success rate.

Objective To observe the clinical efficacy of combined therapy of Xuesaitong and routine Western Medicine in treating stable angina pectoris. Methods 120 cases of stable angina pectoris were randomly divided into treatment group and control group, with 60 cases in each group. Intravenous Nitrates, cardiac muscle nutrieeufical and antihypertensive medicine were administrated to the both groups. Xuesaitong injection was intravenous dripped to patients in the treatment group with 200 mg/d for 10 days. Results The total effective rate was 97.7% in the treatment group and 80.3%in the control group. There was significant difference between the two groups (P＜0.05). Conclusion Integrated therapy of xuesaitong injection and ratine Western Medicine has a great efficacy in treating patients with stable angina pectoris.

Aim To study the inhibition of glutathione-S-transferase by dihydromyricetin and its kinetics analysis in liver of mice.Methods Mouse liver cytochyma enzyme was obtained by different velocity centrifugation,the mouse liver glutathione-S-transferase of michaelis constant(Km),maximum velocity(Vmax)and the inhibition of glutathione-S-transferase by dihydromyricetin of 50% inhibiting concentration(IC50),inhibition constant(Ki),the type of inhibition were calculated by Lineweaver-Burk and the low of semi-effect-probit.Results It was found that dihydromyricetin inhibited the glutathione-S-transferase activity with an IC50 of(121.14?13.66)?mol?L~-1.Kinetics analysis showed the Km was 0.1460 mmol?L~-1 and Vmax was 175.44 U?mg~-1 for reduced glutathione(GSH)substrate and 0.0937 mmol?L~-1(Km)and 212.77 U?mg~-1(Vmax)for 1-chloro-2,4,-dinitrobenzene(CDNB)substrate.Kinetics studies of dihydromyricetin on glutathione-S-transferase showed the inhibition was competitive with GSH and noncompetitive with CDNB,and the inhibition constant was 0.22 mmol?L~-1 with GSH and 0.54 mmol?L~1 with CDNB.Conclusion Dihydromyricetin can inhibit the glutathione-S-transferase activity in liver of mice.